Jupiter Neurosciences Inc., a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based platform, ...

JUPITER, FL - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company currently valued at $34.1 million, has announced a partnership with Catalent (NYSE:CTLT) Pharma ...

Jupiter Neurosciences (JUNS) announced it has entered into an agreement with Catalent Pharma Solutions for the production of JOTROL softgel ...

Jupiter, Florida, Feb. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, ...

The global softgel encapsulation machine market is poised for substantial growth over the next decade, with a projected valuation of USD 178.8 million by 2035. This represents a c ...

As per Future Market Insights (FMI), the Southeast Asia submersible pumps market is expected to reach USD 1,294.8 million in 2035. It is anticipated to showcase steady growth at a CAGR of 5.7% between ...

Strides Pharma Science in its consolidated financial results for the quarter Q3FY25 ended December 31, 2024 reported revenues of Rs. 1,153.7 crore with a growth 14.6% YoY in Q3FY25. The PAT stood at ...

Revenue increased 15% YoY at ₹1,153.7 crore from ₹1,005.8 crore in Q3 FY24, marking a consistent business growth.

Strides Pharma Science is well on track to achieve the FY25 outlook of $275 million-$290 million, post-demerger.

The company posted strong sales growth in 2024, though share-based compensation expenses weighed on its bottom line.

Detailed price information for Nextleaf Solutions Ltd (OILS-CN) from The Globe and Mail including charting and trades.